top of page
About Us
Karkinos Clinical Research Consultants LLC is a trial management and consulting company focused on global early phase trials. We specialize in complex Phase 1/2 trials, including dose escalations, Project Optimus designs, and adaptive trials of novel oncology therapies.
​
We are highly experienced researchers who understand the unique challenges of early phase drug development, including slot and cohort management, compliant tissue sample collections, and management of sample analyses for safety review meetings (eg, pharmacokinetic (PK) and related analyses).
​
Our team takes care to not only to plan your early phase trial for success, but also for the success of future late phase trials.
About Our Name
Karkinos (kar-KEE-nos), from the Ancient Greek Καρκίνος, means "crab", and it's the original word for cancer. Hippocrates first used the term over 2,400 years ago to describe tumors whose spreading lesions reminded him of a crab's shape. When the Roman physician Celsus later translated karkinos into Latin, the term "cancer" was born. The same Greek root lives on in words like carcinoma and carcinogen.
​
At Karkinos Clinical Research Consultants, our name honors the ancient origins of oncology while we focus on its future: guiding you through the ever evolving clinical trial landscape, shaping tomorrow's cancer care.
Trust us to navigate the complexities of early phase oncology trials with precision and care.
Expert Team
Brandy Hemmer, MS
Brandy is the Founder and Principal Consultant at Karkinos Clinical Research Consultants. Brandy has extensive experience starting up and managing Phase 1/2 trials, including multi-trial drug programs, at CROs and pharmaceutical companies. Averaging 2-3 global Phase 1/2 trials started-up per year, Brandy has exceeded or achieved major startup milestones on each one.
​
Brandy is experienced with all types of oncology drugs, including but not limited to ADCs, immunotherapy (eg, Checkpoint inhibitors), CAR-T cell therapy, T-cell engagers, stem cell transplant, and combotherapies. She is also experienced with complex, adaptive design and modular trials, and trials involving investigational in vitro diagnostics (IVD), including IVDR submissions in Europe.
bottom of page